Publications by authors named "Mark Versavel"

Claim this Profile
A
A Phase 2 Proof-of-Concept, Randomized, Placebo-Controlled Trial of CX-8998 in Essential Tremor.
Spyros Papapetropoulos, Margaret S Lee, Stacey Versavel, Evan Newbold, Hyder A Jinnah, Mark Versavel

Mov Disord· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
Himanshu Naik, Deb J Steiner, Mark Versavel, Joanne Palmer, Regan Fong

Clin Transl Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive.
Yuan Zhao, Mark Versavel, Beth Tidemann-Miller, Romy Christmann, Himanshu Naik

Clin Drug Investig· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers.
Joi Dunbar, Mark Versavel, Yuan Zhao, Simon Tate, Valerie Morisset

Clin Pharmacol Drug Dev· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
John A Hey, Jeremy Y Yu, Mark Versavel, Susan Abushakra, Petr Kocis

Clin Pharmacokinet· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.
Robert R Edwards, Robert H Dworkin, Dennis C Turk, Martin S Angst, Raymond Dionne, Mark Versavel

Pain· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP-432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects.
John J Sramek, Larry W Hardy, Peter Bieck, Cynthia Zamora, Mark Versavel

CNS Neurosci Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system.
Shannon M Smith, Dagmar Amtmann, Robert L Askew, Jennifer S Gewandter, Matthew Hunsinger, Mark Versavel

Pain· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inclusion and exclusion criteria for epilepsy clinical trials-recommendations from the April 30, 2011 NINDS workshop.
Evan Fertig, Brandy E Fureman, Gregory K Bergey, Mary Ann Brodie, Dale C Hesdorffer, Mark Versavel

Epilepsy Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Charles L Bowden, Eduard Vieta, Kathleen S Ice, Jeffrey H Schwartz, Paul P Wang, Mark Versavel

J Clin Psychiatry· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
Michelle Stewart, Melissa P DelBello, Mark Versavel, David Keller

J Child Adolesc Psychopharmacol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
Kuan Gandelman, Jeffrey A Alderman, Paul Glue, Ilise Lombardo, Robert R LaBadie, Mark Versavel

J Clin Psychiatry· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
Melissa P DelBello, Mark Versavel, Kathleen Ice, David Keller, Jeffrey Miceli

J Child Adolesc Psychopharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study.
Thomas Tölle, Rainer Freynhagen, Mark Versavel, Uwe Trostmann, James P Young

Eur J Pain· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study.
Diego Garcia-Borreguero, John Winkelman, Alieu Adams, Amanda Ellis, Mark Morris, Mark Versavel

Sleep Med· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial.
Robert van Seventer, Hilary A Feister, James P Young, Malcolm Stoker, Mark Versavel

Curr Med Res Opin· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study.
M R Walters, Markku Kaste, K R Lees, Hans C Diener, M Hommel, Mark Versavel

Cerebrovasc Dis· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-effect relationships of alcohol in a computerised psychometric test system.
Mark Versavel, Michael Zühlsdorf, Sigrun Unger, Georg Wensing, Jochen Kuhlmann

Arzneimittelforschung· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Rainer Sabatowski, Rafael Gálvez, David A Cherry, Florence Jacquot, Emmanuelle Vincent, Mark Versavel

Pain· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.
Jan-Willem Elting, Geert A Sulter, Markku Kaste, Kennedy R Lees, Hans C Diener, Mark Versavel

Stroke· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis